Having demonstratedJS25 as a potent inhibitor of BTK in biochemicalassays, we turned to its characterization in standard cell lines ofhematological cancers, related to an abnormal expression of BTK, includingBL, DLBCL, CLL, AML, and acute promyelocytic leukemia (APML). This evidence concerns the gene BTK and acute promyelocytic leukemia.